Chronic Diarrhea Clinical Trial
Official title:
Secondary Lactose Intolerance Due to Chronic Norovirus Infection in Renal Transplant Recipients
The objective of this study is to determine the prevalence of secondary lactose intolerance
in renal transplant recipients (RTR) with chronic norovirus infection.
In the investigators cohort of 1000 renal transplant recipients (RTRs) in the University
Hospital of Zurich, the investigators are currently aware of 10 patients with chronic
norovirus infection, which was proven by positive polymerase chain reaction (PCR) analysis
of recent stool samples, whereas chronic virus shedding is defined as more than two PCR
positive samples in an interval of at least one month. Concomitant viral (other than
norovirus), bacterial or parasitic (particularly Gardia lamblia) intestinal infections are
excluded by negative stool cultures and PCR analyses, respectively. Main exclusion criterion
for the present case series is a concomitant intestinal infection (other than norovirus) and
primary lactose intolerance, which is previously excluded by absence of the CC genotype of
the DNA variant -13910 T/C upstream in the LCT gene. After obtaining written and oral
informed consent, the investigators perform a lactose hydrogen breath (LH2BT) test and a
lactose tolerance test (LTT) in all eligible RTRs with proven chronic norovirus infection
irrespective of current abdominal symptoms.
The study population (N=10) is divided into two groups according to the gastrointestinal
symptoms (asymptomatic versus symptomatic, such as chronic diarrhoea or diffuse abdominal
discomfort). The investigators chose the cut-off three or more stools per day as indicative
of diarrhoea for the purpose of this study. RTRs with otherwise unexplainable chronic
diarrhoea but absent norovirus infection serve as control group (N=10).
In the investigators cohort of 1000 renal transplant recipients (RTRs) in the University
Hospital of Zurich, the investigators are currently aware of 10 patients with chronic
norovirus infection, which was proven by positive polymerase chain reaction (PCR) analysis
of recent stool samples, whereas chronic virus shedding is defined as more than two PCR
positive samples in an interval of at least one month. Concomitant viral (other than
norovirus), bacterial or parasitic (particularly Gardia lamblia) intestinal infections are
excluded by negative stool cultures and PCR analyses, respectively. Main exclusion criterion
for the present case series is a concomitant intestinal infection (other than norovirus) and
primary lactose intolerance, which is previously excluded by absence of the CC genotype of
the DNA variant -13910 T/C upstream in the LCT gene. After obtaining written and oral
informed consent, the investigators perform a lactose hydrogen breath (LH2BT) test and a
lactose tolerance test (LTT) in all eligible RTRs with proven chronic norovirus infection
irrespective of current abdominal symptoms.
The study population (N=10) is divided into two groups according to the gastrointestinal
symptoms (asymptomatic versus symptomatic, such as chronic diarrhoea or diffuse abdominal
discomfort). The investigators chose the cut-off three or more stools per day as indicative
of diarrhoea for the purpose of this study. RTRs with otherwise unexplainable chronic
diarrhoea but absent norovirus infection serve as control group (N=10).
Lactose Lactose is a disaccharide sugar that is found most notably in milk and is formed
from galactose and glucose. Lactose makes up around 2~8% of milk (by weight), although the
amount varies among species and individuals. It is extracted from sweet or sour whey. The
intestinal villi secrete the enzyme called lactase (β-D-galactosidase) to digest it. This
enzyme cleaves the lactose molecule into its two subunits, the simple sugars glucose and
galactose, which can be absorbed. Since lactose occurs mostly in milk, in most mammals the
production of lactase gradually decreases with maturity due to a lack of constant
consumption. In people who are lactose intolerant, lactose is not broken down and provides
food for gas-producing gut flora, which can lead to diarrhoea, bloating, flatulence, and
other gastrointestinal symptoms.
Lactose H2 breath test (LH2BT) The LH2BT is performed according to Newcomer et al. [8].
After an overnight fast of at least 12 hours, a basal breath sample is collected. RTRs are
allowed to drink water and follow their usual medication regimen during the entire
examination. After the basal sample is being collected, the RTRs are given 25 g of lactose
dissolved in 250 ml of water to drink. Lactose is a natural disaccharide of D-glucose and
D-galactose ("milk sugar"), which is contained in all dairy products. For purpose of the
study, it is provided as lactose powder (or milk powder) with the AlveoSampler™ Lactose Kit
with 25 grams of orange flavored lactose (Figure 1). Samples of end expiratory breath are
then collected at 30, 60, 90 and 120 minutes after the oral lactose load to measure the
concentration of hydrogen (H2), which is considered significantly increased and indicative
of lactose maldigestion when above the value of 20 ppm [8]. During the test, LTRs are
allowed to engage in normal activities. Only water consumption is permitted throughout the
examination. The test is performed in a well-ventilated room free of fresh painted walls or
objects and with no evidence of any organic solvents or cigarette smoke. The samples are
collected in specially constructed bags, which are provided along with the instrument
(Quintron Instrument Co., Milwaukee, WI, USA, [Figure 1]). Breath H2 concentration is
measured on a Model 12 Microlyser purchased from Quintron Instrument Co. The number of loose
motions and flatulence during the test are also documented.
A-AlveoSamplerTM and Model 12i MicroLyzer (Quintron Instrument Co., WI, USA, [Figure 1]) The
dimensions of the gas chromatograph are: height, 27 cm; width, 35 cm; depth, 23 cm and the
weight 7.3 kg. For the analysis of the hydrogen breath samples the device should be placed
in a room somewhere near the investigation site with stable room temperature. For each
subject and for each study session one gas collection system including discard bag, mouth
piece, stopcock and syringe is needed. Every end-expiratory breath sample collected in the
syringe of the system must be immediately analyzed after collection. No specific software is
needed to generate outcome parameters.
Figure 1: The breath collection system (AlveoSamplerTM) and the gas chromatograph (Model 12i
MicroLyzer, Quintron Instrument Co., WI, USA). The AlveoSampler™ Sytem kits are the economic
and disposable solution for breath-testing. These kits allow for ease of collection and
maximize your return on investment. It permits the technician to manually collect an
alveolar sample in a syringe for immediate analysis.
Single-patient use of this device removes the danger of inter-patient cross-infection and
saves time and money related to the cost of cleaning and sterilizing reusable components.
Each kit comes pre-assembled with the substrate of your choice; Lactose, Fructose, d-Xylose,
or Lactulose. These kits are also available without substrate to utlize other breath-testing
substrates that cannot be bundled with the test kit such as Glucose, Sucrose, and Sorbitol.
Each kit contains:
1 packet of substrate (determined by kit ordered)
1 disposable 35 ml syringe
1 disposable one-way stopcock
1 disposable AlveoSampler™ discard bag
1 set of instructions with analytical record
Catalog Numbers:
QT00828-P - AlveoSampler™ Lactose Kit with 25 grams of orange flavored lactose
Lactose tolerance test (LTT) Following the above mentioned oral administration of 25 g
lactose, blood glucose levels are documented at 0, 60, and 120 minutes, which are performed
with the blood glucose meter "Bayer Ascensia Contour Set" using capillary blood samples. An
increase of blood glucose by less than 1.1 mmol/L in conjunction with the development of
abdominal symptoms is defined diagnostic for lactose intolerance [8].
b. Study Outcome Measures Prevalence of lactose intolerance stated with a positive LH2BT
and/or a positive LTT in RTRs with chronic norovirus infection.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03269305 -
An Audit on Management of Chronic Diarrhea
|
||
Completed |
NCT03876717 -
Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea
|
Phase 4 | |
Not yet recruiting |
NCT03598010 -
Safety, Tolerability and Preliminary Efficacy of Lenodiar Pediatric in Diarrhea
|
N/A | |
Completed |
NCT05690321 -
Opium Tincture Against Chronic Diarrhea - Patients
|
Phase 2 | |
Terminated |
NCT01866774 -
Evaluation of Fecal Calprotectin Screening and a Gastroenterology Questionnaire for Triaging Children With Chronic Abdominal Pain and/or Diarrhea Referred to a Pediatric Gastroenterology Service
|
N/A | |
Completed |
NCT01545063 -
CAre of Patients With PArenteral Nutrition At Home
|
N/A | |
Completed |
NCT05702190 -
Opium Tincture Against Chronic Diarrhea - Healthy
|
N/A | |
Not yet recruiting |
NCT05811091 -
Pathological Patterns in Chronic Diarrhea With Normal Colonoscopy
|
||
Not yet recruiting |
NCT05724381 -
Auramine Phenol Staining Technique for Revealing Different Coccidian Parasites
|
||
Recruiting |
NCT01070277 -
Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea
|
N/A | |
Completed |
NCT02642250 -
Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea
|
Phase 2/Phase 3 | |
Recruiting |
NCT06152289 -
Development of New Diagnostic Tools in Capsule Endoscopy
|
||
Completed |
NCT03270085 -
Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption
|
Phase 2 | |
Completed |
NCT05130047 -
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
|
Phase 2 | |
Recruiting |
NCT03261297 -
Epidemiology of Chronic Diarrhea Among Children Admitted to Gastroenterology Unit at Assuit University Children Hospital
|
N/A | |
Completed |
NCT03143517 -
Fecal Calprotectin Collection Protocol
|